Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary FibrosisRichard J. Allen, Wim Timens, Louise V. Wain et al.|American Journal of Respiratory and Critical Care Medicine|2019Cited by 343
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cellsMaría Molina‐Molina, Ana Montes‐Worboys|BMC Pulmonary Medicine|2018Cited by 106
Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosisBruce D. Uhal, María Molina‐Molina|European Respiratory Journal|2012Cited by 66
Genome-wide association study of susceptibility to idiopathic pulmonary fibrosisRichard J. Allen, Martin D. Tobin, Beatriz Guillén‐Guío et al.|bioRxiv (Cold Spring Harbor Laboratory)|2019Cited by 31
A Randomized, Embedded, Multifactorial Adaptive Platform trial for ILD (REMAP-ILD): The conceptual designTejaswini Kulkarni, Gísli Jenkins, Letícia Kawano-Dourado et al.|Unknown|2023Cited by 2